Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

3,950.00p
   
  • Change Today:
      50.00p
  • 52 Week High: 4,500.00p
  • 52 Week Low: 3,800.00p
  • Currency: UK Pounds
  • Shares Issued: 5.21m
  • Volume: 8,977
  • Market Cap: £205.77m

Bioventix profits will beat forecasts, boost eyed from Siemens link

By Oliver Haill

Date: Monday 22 Aug 2016

LONDON (ShareCast) - (ShareCast News) - Bioventix revealed that revenues and profits will be ahead of expectations for the full year thanks to currency effects and continued demand for its monoclonal antibodies.
Revenue for the year to 30 June will come in at £5.3m, which is at least 11% ahead of the forecast £4.8m and 22% up on the previous year, with profits also confirmed as beating estimates as the cost base has not accelerated.

Encouraged by recent developments from project partner Siemens Healthcare Diagnostics, management said they were confident the troponin antibody will contribute significantly to results in 2018.

Troponin, which was created by Bioventix and is being used by Siemens in a product under development, was highlighted in a presentation at the American Association of Clinical Chemistry, where Siemens described for the first time its development programme.

Bioventix said: "Troponin remains an important product for Bioventix's future performance, as we expect to commence significant sales during the financial year ending 30 June 2018, which will offset revenues from other products which are expected to reduce during this period."

House broker FinnCap said it assume in its base case a European launch in mid-2017, with a US launch in mid-2018.

Pending a conversation with the company, analysts forecast EPS increases for both 2016 and 2017 in be in the range of 13-20%, while estimating net cash at 30 June 2016 of around £5.2m.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 3,950.00p
Change Today 50.00p
% Change 1.28 %
52 Week High 4,500.00p
52 Week Low 3,800.00p
Volume 8,977
Shares Issued 5.21m
Market Cap £205.77m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
84.37% below the market average84.37% below the market average84.37% below the market average84.37% below the market average84.37% below the market average
72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average
Price Trend
63.04% below the market average63.04% below the market average63.04% below the market average63.04% below the market average63.04% below the market average
47.54% below the sector average47.54% below the sector average47.54% below the sector average47.54% below the sector average47.54% below the sector average
Income Not Available
Growth
78.01% above the market average78.01% above the market average78.01% above the market average78.01% above the market average78.01% above the market average
2.86% above the sector average2.86% above the sector average2.86% above the sector average2.86% above the sector average2.86% above the sector average

Bioventix Dividends

  Latest Previous
  1st Interim Special
Ex-Div 08-Apr-21 29-Oct-20
Paid 23-Apr-21 13-Nov-20
Amount 43.00p 53.00p

Trades for 05-Aug-2021

Time Volume / Share Price
11:42 3,000 @ 3,851.00p
11:42 3,000 @ 3,850.00p
15:39 1,250 @ 3,880.00p
16:13 99 @ 3,925.00p
16:06 50 @ 3,920.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
CFO Bruce Hiscock

Top of Page